Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant β 2 -microglobulin gene
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Two siblings, products of a consanguineous marriage, were markedly deficient in both albumin and IgG because of rapid degradation of these proteins, suggesting a lack of the neonatal Fc receptor, FcRn. FcRn is a heterodimeric receptor composed of a nonclassical MHC class I α-chain and β 2 -microglobulin (β 2 m) that binds two ligands, IgG and albumin, and extends the catabolic half-lives of both. Eight relatives of the siblings were moderately IgG-deficient. From sera archived for 35 years, we sequenced the two siblings’ genes for the heterodimeric FcRn. We found that, although the α-chain gene sequences of the siblings were normal, the β 2 m genes contained a single nucleotide transversion that would mutate a conserved alanine to proline at the midpoint of the signal sequence. Concentrations of soluble β 2 m and HLA in the siblings’ sera were <1% of normal. Transfection assays of β 2 m-deficient cultured cells with β 2 m cDNA indicated that the mutant β 2 m supported <20% of normal expression of β 2 m, MHC class I, and FcRn proteins. We concluded that a β 2 m gene mutation underlies the hypercatabolism and reduced serum levels of albumin and IgG in the two siblings with familial hypercatabolic hypoproteinemia. This experiment of nature affirms our hypothesis that FcRn binds IgG and albumin, salvages both from a degradative fate, and maintains their physiologic concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Fc receptor structurally related to MHC class I antigens
Simister, N. E., & Mostov, K. E. (1989) · Nature · doi:10.1038/337184a0 · Cited by 729
Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C., & Anderson, C. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021829 · Cited by 640
Self-citationLeach, J. L., Sedmak, D. D., Osborne, J. M., Rahill, B., Lairmore, M. D., & Anderson, C. L. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.8.3317 · Cited by 348
Self-citation
Cited by
Albumin as a versatile platform for drug half-life extension
Sleep, D., Cameron, J., & Evans, L. R. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.04.023 · Cited by 485
Albumin and its application in drug delivery
Sleep, D. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.993313 · Cited by 464
The Neonatal Fc Receptor (FcRn): A Misnomer?
Pyzik, M., Sand, K. M. K., Hubbard, J. J., Andersen, J. T., Sandlie, I., & Blumberg, R. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01540 · Cited by 429
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
Ulrichts, P., Guglietta, A., Dreier, T., van Bragt, T., Hanssens, V., Hofman, E., Vankerckhoven, B., Verheesen, P., Ongenae, N., Lykhopiy, V., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97911 · Cited by 427
“This nadir is similar to the low IgG titers observed in 2 patients with familial hypercatabolic hypoproteinemia due to aberrant FcRn expression (28, 29), indicating that further infusion of an FcRn antagonist would not result in more profound lowering of IgG levels.”
ResultRediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases
Argyropoulos, C. P., Chen, S. S., Ng, Y.-H., Roumelioti, M.-E., Shaffi, K., Singh, P. P., & Tzamaloukas, A. H. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00073 · Cited by 308
Metadata
- Authors
- Wani, M. A., Haynes, L. D., Kim, J., Bronson, C. L., Chaudhury, C., Mohanty, S., Waldmann, T. A., Robinson, J. M., & Anderson, C. L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-03-20
- Volume
- 103
- Issue
- 13
- Pages
- 5084-5089
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1967874097
- Cited by
- 147
- References
- 3
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.